Please ensure Javascript is enabled for purposes of website accessibility

Challenges Loom for This New Drug

By Brian Orelli, PhD – Updated Apr 7, 2017 at 1:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sanofi's Aubagio needs to find a niche.

Novartis' (NYSE: NVS) Gilenya run as the only drug oral medication to slow the progression of multiple sclerosis has come to an end. The Food and Drug Administration approved Sanofi's (NYSE: SNY) Aubagio yesterday.

Being second to the market can be a tough spot, and if Gilenya's history is any indication, it will be hard to hit the ground running. In the second quarter, nearly two years after being approved, Gilenya's sales finally topped $250 million -- what it takes to annualize out to a blockbuster. When a disease has so many treatment options, doctors often take a wait and see approach to new drugs even when the new drug has some advantages, taken orally versus being injected or infused in Gilenya's case.

Aubagio might be preferred over Gilenya given the safety issues Gilenya has had, but on the efficacy side, it doesn't appear to be that great of a drug. In one clinical trial, Aubagio failed to beat Merck KGaA and Pfizer's (NYSE: PFE) Rebif, an injectable drug.

The biggest threat for Aubagio is actually behind it. The FDA is expected to rule on Biogen Idec's (Nasdaq: BIIB) oral multiple sclerosis drug, BG-12, in December. BG-12 has arguably much better efficacy than Aubagio.

Aubagio's niche might end up being the patients that can't tolerate the more effective drugs. Given the large number of patients and the high prices the drugs can fetch, even grabbing a small piece of the $10 billion -- and growing -- market could tally up to reasonable sales.

And Sanofi has another option to get some more of the market. The company is also working on gaining approval for another multiple sclerosis drug Lemtrada. Last month, the FDA asked the company to reformat the data in the application. A little embarrassing -- a pharma giant should know what charts and figures the FDA wants -- but it's only a minor delay and certainly easier to fix than running another trial.

While Aubagio doesn't have the properties needed to be an instant blockbuster, these three Dow stocks have an X factor that makes them stand out from their illustrious Dow peers. Find out what it is in the Fool's new free report, "The 3 Dow Stocks Dividend Investors Need."

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$37.25 (-3.00%) $-1.15
Pfizer Inc. Stock Quote
Pfizer Inc.
$43.83 (-0.57%) $0.25
Novartis AG Stock Quote
Novartis AG
$74.61 (-1.84%) $-1.40
Biogen Inc. Stock Quote
Biogen Inc.
$195.75 (-1.03%) $-2.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.